Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
- Corporate and Finance
Aug 16, 2021
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights

Aug 5, 2021
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
- COVID-19
Aug 5, 2021
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
- COVID-19
Aug 5, 2021
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
- COVID-19
Aug 4, 2021
Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021
- Corporate and Finance
Jul 6, 2021
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
- COVID-19
Jun 30, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021
- Statement
- COVID-19
Jun 30, 2021
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
- Statement
- COVID-19
Jun 22, 2021
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
- Corporate and Finance
Jun 17, 2021

Show per page